1. A slipcover arrangement for a dining room chair having a seat with a seat width and a seat depth, a back rising from a rear end of the seat and having a back width and a back height, and at least one leg for maintaining the seat at a seat height, the arrangement comprising:
a pair of seat panels adapted to cover at least portions of each side of a seat to be covered while leaving an uncovered area on the seat between the seat panels in the direction of the seat width, each seat panel having a length for extending a full seat depth from the back of a chair to be covered, to a point below a front end of the seat to be covered;
a chasuble having a width to cover the uncovered area of the seat to be covered, and a total length for extending from a point below the front end of the seat to be covered, across the seat depth, up along a front surface of the back of the chair to be covered, across a top of the back and at least down part of a rear surface of the back;
wrapping means connected to the chasuble for extending around at least part of the back for holding the chasuble over the seat panels and to the chair to be covered; and
a skirt for engaging around the seat to be covered and for extending from the seat down a portion of the seat height, the skirt defining a front gap that is covered or spanned by a jumper portion of the chasuble.
2. The slipcover of claim 1, wherein each seat panel has a width of less than the seat width, and a length of more than the seat depth.
3. The slipcover of claim 1, wherein each seat panel includes at least one slit for receiving a portion of a dining room chair arm connected to the seat to be covered.
4. The slipcover of claim 1, the skirt comprising a pair of skirt portions with a pair of front connectors for connecting front parts of the skirt portions to each other to form the gap, and a pair of rear connectors for connecting rear parts of the skirt portions.
5. The slipcover of claim 1, wherein the chasuble comprises the jumper portion for covering a front of the chair to be covered from the front end of the seat down to the point below the front end of the seat to be covered, a seat portion for extending across the seat depth, a first back portion for extending up along the front surface of the back of the chair to be covered and across the top of the back, and a second back portion for extending down a rear surface of the back.
6. The slipcover of claim 5, wherein the chasuble has a waist extending near a junction between the seat portion and the first back portion, the wrapping means includes a band at the waist for securing the waist of the chasuble to the back of the chair to be covered.
7. The slipcover of claim 5, wherein the chasuble includes a pair of side wings extending from opposite sides of the first back portion for wrapping around the back of the chair to be covered, and at least one connecter for connected the wings to each other at the rear surface of the back, the second back portion being adapted to cover the connected wings at the rear surface of the back.
8. The slipcover of claim 7, wherein each side wing comprises an upper wing for wrapping around an upper part of the back and a lower wing for engaging around a lower part of the back so that an arm of the chair to be covered which is connected to the back is accommodated between the upper and lower wings, and connectors for connecting the upper wings to each other and for connecting the lower wings to each other.
9. The slipcover of claim 8, wherein the chasuble includes a corner portion connected to, and extending downwardly from each lower wing for extending around rear corners of the seat to be covered.
10. The slipcover of claim 1, wherein the wrapping means comprise a plurality of elastic tabs for connecting portions of the chasuble that are wrapped around to the rear surface of the back, the chasuble being sufficiently long so that a portion of the chasuble covers the tabs at the rear surface of the back.
11. The slipcover of claim 1, including connectors for connecting the jumper portion of the chasuble to the skirt on opposite sides of the gap.
12. The slipcover of claim 1, wherein the pair of seat panels are fixed to opposite sides of a seat portion of the chasuble.
13. A slipcover arrangement for a dining room chair having a seat with a seat width and a seat depth, a back rising from a rear end of the seat and having a back width and a back height, and at least one leg for maintaining the seat at a seat height, the arrangement comprising:
a pair of seat panels adapted to cover at least portions of each side of a seat to be covered while leaving an uncovered area on the seat between the seat panels in the direction of the seat width, each seat panel having a length for extending a full seat depth from the back of a chair to be covered, to a point below a front end of the seat to be covered;
a chasuble having a width to cover the uncovered area of the seat to be covered, and a total length for extending from a point below the front end of the seat to be covered, across the seat depth, up along a front surface of the back of the chair to be covered, across a top of the back and down a rear surface of the back;
wrapping means connected to the chasuble for extending around at least part of the back for holding the chasuble over the seat panels and to the chair to be covered;
each seat panel have a width of less than the seat width, and a length of more than the seat depth, each seat panel includes at least one slit for receiving a portion of a dining room chair arm connected to the seat to be covered; and
a skirt for engaging around the seat to be covered and for extending from the seat down a portion of the seat for holding the chasuble and the side panels to the chair, the skirt defining a front gap that is covered by a jumper portion of the chasuble.
14. The slipcover of claim 13, wherein the skirt comprises a pair of skirt portions with a pair of front connectors for connecting front parts of the skirt portions to each other to form the gap covered by the jumper portion and a pair of rear connectors for connecting rear parts of the skirt portions to each other.
15. The slipcover of claim 14, wherein the chasuble comprises the jumper portion for covering a front of the chair to be covered from the front end of the seat down to the point below the front end of the seat to be covered, a seat portion for extending across the seat depth, a first back portion for extending up along the front surface of the back of the chair to be covered and across the top of the back, and a second back portion for extending down a rear surface of the back.
16. The slipcover of claim 15, wherein the chasuble has a waist extending near a junction between the seat portion and the first back portion, the wrapping means include a band at the waist for securing the waist of the chasuble to the back of the chair to be covered.
17. The slipcover of claim 16, wherein the chasuble includes a pair of side wings extending from opposite sides of the first back portion for wrapping around the back of the chair to be covered, and at least one connecter for connecting the wings to each other at the rear surface of the back, the second back portion being adapted to cover the connected wings at the rear surface of the back.
18. The slipcover of claim 17, wherein each side wing comprises an upper wing for wrapping around an upper part of the back and a lower wing for engaging around a lower part of the back, so that an arm of the chair to be covered which is connected to the back is accommodated between the upper and lower wings, and connectors for connecting the upper wings to each other and for connecting the lower wings to each other, the chasuble including a corner portion connected to, and extending downwardly from each lower wing for extending around rear corners of the seat to be covered.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed:
1. A compound selected from the formulas I or II:
186
wherein:
R1 is selected from H, OH or the C1-C12 esters (straight chain or branched) or C1-C12 (straight chain or branched or cyclic) alkyl ethers thereof, or halogens; or C1-C4 halogenated ethers including triflouromethyl ether and trichioromethyl ether
R2, R3, R4, R5, and R6 are independently selected from H, OH or the C1-C12 esters (straight chain or branched) or C1-C12 alkyl ethers (straight chain or branched or cyclic) thereof, halogens, or C1 -C4 halogenated ethers including trifiouromethyl ether and trichloromethyl ether, cyano, C1-C6alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH
X is selected from H, C1-C6 alkyl, cyano, nitro, trifluoromethyl, halogen;
n is2or3;
Y is selected from:
a) the moiety:
187
wherein R7 and R8 are independently selected from the group of H, C1-C6 alkyl, or phenyl optionally substituted by CN, C1-C6 alkly (straight chain or branched), C1-C6 alkoxy (straight chain or branched), halogen, OH, CF3, or OCF3;
b) a five-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, NH, N(C1C4 alkyl)-, N, and S(O)m-, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, CO2H, CN, CONHR1-, NH2-, C1-C4 alkylamino, di(C1-C4)alkylanino, NHSO2R1-, NHCOR1-, NO2, and phenyl optionally substituted with 1-3 (C1-C4)alkyl;
c) a six-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of O, NH, N(C1C4 alkyl)-, N, and S(O)m-, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, CO2H-, CN, CONHR1-, NH2-, C1-C4 alkylamino, di(C1-C4)alkylamino, NHSO2R1, NHCOR1-, NO2, and phenyl optionally substituted with 1-3 (C1-C4)alkyl;
d) a seven-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of O, NH, N(C1C4 alkyl)-, N, and S(O)m-, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, CO2H-, CN, CONHR1-, NH2-, C1-C4 alkylamino, di(C1-C4)alkylamino, NHSO2R1-, NHCOR1-, NO2, and phenyl optionally substituted with 1-3 (C1-C4)alyl;; or
e) a bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing up to two heteroatoms selected from the group consisting of O, NH, N(C1C4 alkyl)-, and S(O)m-, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, CO2H-, CN, CONHR1-, NH2-, C1-4 alkylamino, di(C1-C4)alkyiamino, NHSO2R1-, NHCOR1-, NO2, and phenyl optionally substituted with 1-3 (C1-C4) alkyl; and the pharmaceutically acceptable salts thereof.
2. A compound of claim 1 wherein:
R1 is selected from H, OH or the C1-C4 esters or alkyl ethers thereof, halogen;
R2, R3, R4, R5, and R6 are independently selected from H, OH or the C1-C4 esters or alkyl ethers thereof, halogen, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH;
X is selected from H, C1-C6 alkyl, cyano, nitro, triflouromethyl, halogen;
Y is the moiety
188
R7 and R8 are selected independently from H, C1-C6 alkyl, or combined by -(CH2)p-, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 aLkylsulfonyl, hydroxy (C1-C4)alkyl, CO2H, CN, CONH(C1-C4), NH2, C1-C4 allylamino, di(C1-C4)alkylamino, NHSO2(C1-C4), NHCO(C1-C4), and NO2; or a pharmaceutically acceptable salt thereof.
3. A compound of claim 1 wherein:
R1 is OH;
R2, R3, R4, R5, and R6 are independently selected from H, OH or the C1-C4 esters or alkyl ethers thereof, halogen, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH;
X is selected from the group of Cl, NO2, CN, CF3, or CH3;
Y is the moiety
189
R7 and R8 are concatenated together as -(CH2)r-, wherein r is an integer of from 4 to 6, to form a ring optionally substituted by up to three subsituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, CO2H, CN, CONH(C1-C4), NH2, C1-C4 alkylamino, di(C1-C4)alkylamino, NHSO2(C1-C4), NHCO(C1-C4), and NO2; or a pharmaceutically acceptable salt thereof.
4. A compound of claim 1 which is 5-Benzyloxy-2-(4-ethoxy-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
5. A compound of claim 1 which is 5-Benzyloxy-2-phenyl-3-methyl-1-4 (2-azepan-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
6. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-4-(2-azepan-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
7. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-4-(2-diisopropylamino-1-ylethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
8. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-4-(2-butyl-methylamino-1-ylethoxy)-benzyl- 1H-indole or a pharmaceutically acceptable salt thereof.
9. A compound of claim 1 which is 5-Benzyloxy-2-(4benzyloxy-phenyl)-3-methyl-1-4 dimethylamino)-ethoxy-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
10. A compound of claim 1 which is 5-Benzyloxy-2-(4benzyloxy-phenyl)-3-methyl-1-(4-(2-(2-methyl-piperidin-1-yl)-ethoxy-benyl )-1H-indole or a pharmaceutically acceptable salt thereof.
11. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1 – (4-2-(3-methyl-piperidin-1 -yl)-ethoxy-benzyl)-1H-indole or a pharmaceutically acceptable salt thereof.
12. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1- (4-2-(4-methyl-piperidin-1 -yl)-ethoxy-benzyl)-1H-indole or a pharmaceutically acceptable salt thereof.
13. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-4-2-((cis)-2,6-Dimethyl-piperidin-1-yl)-ethoxy-benzyl 1H-indole or a pharmaceutically acceptable salt thereof.
14. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-4-2-(1,3,3-trimethyl-6-aza-bicyclo3.2.loct-6-yl)-ethoxy-benzyl -1H -indole or a pharmaceutically acceptable salt thereof.
15. A compound of claim 1 which is (1S, 4R)-5-Benzyloxy-2 -(4 -benzyloxy-phenyl)-3-methyl(4-2-(2-Aza-bicyclo 2.2.1 hept-2-yl)-ethoxy-benzyl -1H-indole or a pharmaceutically acceptable salt thereof.
16. A compound of claim 1 which is 5-Benzyloxy-2-(4-flouro-phenyl)-3-methyl-1-4-(2-azepan-1 -yl-ethoxy)-benzyl- 1H-indole or a pharmaceutically acceptable salt thereof.
17. A compound of claim 1 which is 5-Benzyloxy-2-(4-flouro-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
18. A compound of claim 1 which is 5-Benzyloxy-2-(4-chloro-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
19. A compound of claim 1 which is 5-Benzyloxy-2-3,4methylenedioxy-phenyl-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
20. A compound of claim 1 which is 5-Benzyloxy-2-4isopropoxy-phenyl-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceuically acceptable salt thereof.
21. A compound of claim 1 which is 5-Benzyloxy-2-4methyl-phenyl-3-methyl-1-4(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
22. A compound of claim 1 which is 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-5-benzyloxy-2-(3-benzyloxy-phenyl)-3-methyl-1H-indole or a pharmaceutically acceptable salt thereof.
23. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-3-fluoro-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
24. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-3-fluoro-phenyl)-3-methyl-1-4-(2-azepan-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
25. A compound of claim 1 which is 5-Benzyloxy-2-(3-methoxy-phenyl-1-4(2-piperidin-1-yl-ethoxy)-benzyl-3-methyl-1H-indole or a pharmaceutically acceptable salt thereof.
26. A compound of claim 1 which is 5-Benzyloxy-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-2-(4-trifluoromethoxy-phenyl)-1H-indole or a pharmaceutically acceptable salt thereof.
27. A compound of claim 1 which is (2-4-5-Benzyloxy-2-4-benzyloxy-phenyl)-3-methyl-indol-1-yl-methyl-phenoxy-ethyl)-cyclohexyl-amine or a pharmaceutically acceptable salt thereof.
28. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-4-methylpiperazin-1-yl)-ethoxy-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
29. A compound of claim 1 which is 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-5-benzyloxy-2-(3-methoxy-phenyl)-3-methyl- 1H-indole or a pharmaceutically acceptable salt thereof.
30. A compound of claim 1 which is 4-(3-Methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole(HCl).
31. A compound of claim 1 which is 4-(3-Methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-2-yl-phenol hydrochloride (HCl).
32. A compound of claim 1 which is 3-Methyl-2-phenyl-1-4(2-piperidine-1-yl-ethoxy)-benzyl-1H-indol-5-ol (HCl).
33. A compound of claim 1 which is 4-5-Methoxy-3-methyl-1-4-2-(piperidin-1-yl)-ethoxy-benzyl-1 H -indol-2-yl)-phenol or a pharmaceutically acceptable salt thereof.
34. A compound of claim 1 which is 2-(4-methoxy-phenyl)-3-methyl-1-4-2-(piperidin-1-yl)-ethoxy-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
35. A compound of claim 1 which is 5-Methoxy-2-(4-methoxy-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole (HCL).
36. A compound of claim 1 which is 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-5-methoxy-2-(4-methoxy-phenyl)-3-methyl-1H-indole (HCL).
37. A compound of claim 1 which is 2-(4-Ethoxy-phenyl)-3-methyl-1-4 -(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
38. A compound of claim 1 which is 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-2-(4-ethoxy-phenyl)-3-methyl-1H-indol-5-ol or a phanraceutically acceptable salt thereof.
39. A compound of claim 1 which is 4-5-Fluoro-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-2-yl-phenol (HCl).
40. A compound of claim 1 which is 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-3-methyl-2-phenyl-1H-indol-5-ol (HCl).
41. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-3-methyl-1-4-(2-pyrollidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
42. A compound of claim 1 which is 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-2-(4hydroxy-phenyl)-3-methyl-1H-indol-5-ol (HCl).
43. A compound of claim 1 which is l-4(2-Azepan-1-yl-ethoxy)-benzyl-2-(4hydroxy-phenyl)-3-methyl-1H-indol-5-ol Acetate Salt.
44. A compound of claim 1 which is 1-4-(2-Azocan-1-yl-ethoxy)-benzyl-2-(4hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
45. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-3-methyl-1-4-(2-dimethyl-1-yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
46. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-3-methyl-1-4-(2-diethyl-1-yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
47. A compound of claim 1 which is 1-4-(2-Dipropylamino-ethoxy)-benzyl-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
48. A compound of claim 1 which is 1-4(2-Dibutylamino-ethoxy)-benzyl-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
49. A compound of claim 1 which is 1-4-(2-Diisopropylaminoethoxy)-benzyl-2-(4-hydroxy-phenyl)-3-methyl- 1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
50. A compound of claim 1 which is 1-4-2-(Butyl-methyl-ammio)-ethoxy-benzyl -2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
51. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-3-methyl-1-4-2-(2-methyl-piperidin-1-yl)-ethoxy-benzyl- 1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
52. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-3-methyl-1-4-2-(3-methyl-piperdin-1-yl)-ethoxy-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
53. A compound of claim 1 which is 2-(4Hydroxy-phenyl)-3-methyl-1-4-2-(4-methyl-piperidin-1-yl)-ethoxy-benzyl-1H-indol-5-ol (HCl).
54. A compound of claim 1 which is 1-4-2-(3,3-Dimethyl-piperidin-1-yl)-ethoxy-benzyl-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
55. A compound of claim 1 which is 1-4-2-((cis)-2,6Dimethyl-piperidin-1-yl)ethoxy-benzyl-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
56. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-1-4-2-(4-hydroxy-piperidin-1 -yl)-ethoxy-benzyl-3-methyl- 1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
57. A compound of claim 1 which is (1S,4R)-1-4-2-(2-Aza-bicyclo 2.2.1 hept-2-yl)-ethoxy-benzyl-2-(4-hydroxy-phenyl)-3-methyl- 1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
58. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-3-methyl-1-4-2-(1,3,3-trimethyl-6-aza-bicyclo3.2.1oct-6yl)-ethoxy-benzyl-1H-indol-5-ol or a phanmaceutically acceptable salt thereof.
59. A compound of claim 1 which is 2-(4Fluoro-phenyl)-3-methyl-1-4-(2-piperidine-1-yl-ethoxy)-benzyl-1H-indol-5-ol (HCl).
60. A compound of claim 1 which is 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-2-(4fluoro-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
61. A compound of claim 1 which is 2-(3-Methoxy4-hydroxy-phenyl)-3-methyl- l-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol (HCl).
62. A compound of claim 1 which is 2-Benzo1,3dioxol-5-yl-3-methyl-1-4(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol (HCL).
63. A compound of claim 1 which is 2-(4-Isopropoxy-phenyl)-3-methyl-1-4-(2-piperidin-1 -yl-ethoxy)-benzyl- 1H-indol-5-ol (HCl).
64. A compound of claim 1 which is 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-2-(4-isopropoxy-phenyl)-3-methyl-1H-indo-5-ol (HCl).
65. A compound of claim 1 which is 2-(4-Cyclopenyloxy-phenyl)-3-methyl-1-4-(2-piperidin-1 -yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
66. A compound of claim 1 which is 3-Methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-2-(4-trifluoromethyl-phenyl)-l1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
67. A compound of claim 1 which is 3-Methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-2-p-tolyl-)-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
68. A compound of claim 1 which is 2-(4Chloro-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol (HCL).
69. A compound of claim 1 which is 2-(2,4-Dimethoxy-phenyl)-3-methyl-1-4(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
70. A compound of claim 1 which is 2-(3-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
71. A compound of claim 1 which is 1-4(2-Azepan-1-yl-ethoxy)-benzyl-2-(3-hydroxy-phenyl)-3-methyl-1H-indole-5-ol or a pharmaceutically acceptable salt thereof.
72. A compound of claim 1 which is 2-(3-Fluoro4hydroxy-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
73. A compound of claim 1 which is 2-(3-Fluoro-4-hydroxy-phenyl)-3-methyl-1-4(azepan-1 -yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
74. A compound of claim 1 which is 2-(3-Methoxy-phenyl)-3-methyl-1-4-(2-piperidin-1 -yl-ethoxy)-benzyl- 1H-indole-5-ol or a pharmaceutically acceptable salt thereof.
75. A compound of claim 1 which is 3-Methyl-1-4(2-piperidin-1-yl-ethoxy)-benzyl-2-(4-trifiuoromethoxy-phenyl)-1H-indole-5-ol or a pharmaceutically acceptable salt thereof.
76. A compound of claim 1 which is 3-Chloro-2-(4hydroxy-phenyl)-1-4-(2-pyrrolidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol (HCl).
77. A compound of claim 1 which is Removal of benzyl ethers to render 3-Chloro-2-(4hydroxy-phenyl)-1-4(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol (HCl).
78. A compound of claim 1 which is 3-Chloro2-(4-hydroxy-phenyl)-1-4-(2-azepan-1-yl-ethoxy)-benzyl-1H-indol-5-ol (HCl).
79. A compound of claim 1 which is 3-Chloro-2-(4-hydroxy-2-methyl-phenyl)-1-4-(2-piperidin-1-yl-ethoxy)-benzyl- 1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
80. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-3-ethyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol (HCl).
81. A compound of claim 1 which is 5-Hydroxy-2-(4-Hydroxy-phenyl)-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole-3-arbonitrile (HCl).
82. A compound of claim 1 which is 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-5-hydroxy-2-(4-hydroxy-phenyl)-1H-indole-3-abonitiie (HCl).
83. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-chloro-1-4-(2-piperidin-1-yl-ethoxy)-benzyl- 1H-indole or a pharmaceutically acceptable salt thereof.
84. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-chloro-1-4-(2-azepan-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
85. A compound of claim 1 which is 5-Benzyloxy-2-(2-methyl-4-benzyloxy-phenyl)-3-chloro-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
86. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-ethyl-1-4(2-piperidin -1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
87. A compound of claim 1 which is 5-Benzyloxy-2-(4benzyloxy-phenyl)-3-cyano-1-4-(2-piperidin-1-yl-ethoxy)-benzyl- 1H-indole or a pharmaceutically acceptable salt thereof.
88. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-cyano-1-4-(2-azepan-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
89. A compound of claim 1 which is Di-propionate of 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol (HCl).
90. A compound of claim 1 which is Di-pivalate of 1-4-(2-Azepan-1-yl-ethoxy)-benzyl-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol (HCl).
91. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-1-4-(3-piperidin-1-yl-propoxy)-benzyl-3-methyl-1H-indole or a pharmaceutically acceptable salt thereof.
92. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-3-methyl-1-4–3-(piperidin-1 -yl)-propoxy-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
93. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-1-3-methoxy-4-(2-piperidin-1-yl-ethoxy)-benzyl-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
94. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-1-3-methoxy-4-(2-azepan-1-yl-ethoxy)-benzyl-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
95. A compound of claim 1 which is 5-Benzyloxy-2-(4benzyloxy-phenyl)-3-methyl-1-3-Methoxy-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
96. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-2-Methoxy4(2-azepan-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
97. A compound of claim 1 which is Di-pivalate ester of 2-(4Hydroxy-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
98. A compound of claim 1 which is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indole or a pharmaceutically acceptable salt thereof.
99. A compound of claim 1 which is 5-Benzyloxy-2-(3-benzyloxy-phenyl)-3-methyl-1-4(2-piperidin-1-yl-ethoxy)-benzyl- 1H-indole or a pharmaceutically acceptable salt thereof.
100. A compound of claim 1 which is 2-(4Hydroxy-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
101. A compound of claim 1 which is 2-(4Hydroxy-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol methiodide.
102. A compound of claim 1 which is 2-(4Hydroxy-phenyl)-3-methyl-1-4-(2 direthyl-1-yl-ethoxy)-benzyl-1H-indol-5-ol methiodide.
103. A pharnaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceuticaly acceptable carrier or excipient.
104. A method of treating or preventing bone loss in a mammal, the method comprising administering to a mammal in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
105. A method of treatng or preventing disease states or syndromes which are caused or associated with an estrogen deficiency in a mammal, the method comprising administering to a mammal in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
106. A method of treating or preventing cardiovascular disease in a mammal, the method comprising administering to a mammal in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
107. A method of treating or preventing disease in a mammal which result from proliferation or abnormal development, actions or growth of endometnal or endomemal-like tissue, the method comprising administering to a mammal in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.